

Prothena is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena's pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Parkinson's disease and a number of other neurodegenerative diseases.



## Our mission is to deliver life-saving therapies for diseases caused by protein dysregulation

By the numbers	<b>160+</b> employees	35+ years leading protein dysregulation science	8 pipeline assets
Our Values	Selfless •	Courageous • Imaginative	• Joyful

## Our pipeline

Prothena's pipeline includes both wholly owned and partnered programs for the potential treatment of Alzheimer's, Parkinson's and a number of other neurodegenerative diseases, as well as rare peripheral amyloid diseases, such as AL amyloidosis and ATTR amyloidosis.



## VIEW FULL PIPELINE

**Birtamimab,** a wholly owned potential first-in-class anti-amyloid antibody for the treatment of AL amyloidosis

**Prasinezumab**, a potential first-in-class alpha-synuclein antibody for the treatment of Parkinson's disease in partnership with Roche


**Coramitug (PRX004),** a potential first-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM) in partnership with Novo Nordisk

**BMS986446 (PRX005),** an anti-tau antibody for the treatment of Alzheimer's disease in partnership with Bristol Myers Squibb

**PRX012,** a wholly owned, single-injection once-monthly anti-amyloid antibody delivered subcutaneously for the treatment of presymptomatic or early symptomatic Alzheimer's disease

**PRX019,** a potential treatment of neurodegenerative diseases in partnership with Bristol Myers Squibb

**PRX123,** a wholly owned potential first-in-class dual  $A\beta$ /tau vaccine designed for the treatment and prevention of Alzheimer's disease





For more information, please visit the Company's website at www.prothena.com and follow the Company on X @ProthenaCorp and LinkedIn @ProthenaCorporationPLC.

